Drugs / Tafalgin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07451522 | Dec 2025 → Mar 2026 overdue | coronary artery disorder | Primorsky Regional General Hospital #1 | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tafalgin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07451522 ↗ |
| Known as | tyrosyl-D-arginyl-phenylalanyl-glycine amide | “Tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amide)” NCT07451522 ↗ |